GlassScriptPhysician profile
Kimberly Noel Miller
NPI 1548814684
$1,684.99
in general payments reported to CMS, 2019-2025
22 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.06 · 2023: $137 · 2024: $424 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $262.66 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $197.63 | 2024-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $196.31 | 2024-2025 | |
| Edwards Lifesciences Corporation | $164.78 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $119.26 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $98.76 | 2025 | Onpattro |
| Novo Nordisk INC | $82.46 | 2025 | Wegovy |
| Amgen INC. | $81.19 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $69.51 | 2024-2025 | |
| Scpharmaceuticals INC. | $67.18 | 2024-2025 | |
| Esperion Therapeutics, INC. | $43.35 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.94 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.19 | 2024-2025 | Lifevest |
| Inari Medical, INC. | $35.00 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals International, Plc | $34.19 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.33 | 2025 | Farxiga |
| Lilly USA, LLC | $25.19 | 2025 | Zepbound |
| Atricure, INC. | $23.60 | 2024 | |
| Merck Sharp & Dohme LLC | $22.06 | 2021 | |
| Cashflow Solutions, LLC | $21.39 | 2025 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Janssen Pharmaceuticals, INC | $17.43 | 2024 | Xarelto |
| Bridgebio Pharma, INC. | $15.58 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.